MIRA INFORM REPORT

Report Date :

09.01.2013

IDENTIFICATION DETAILS

Name :	UNIJULES LIFE SCIENCES LIMITED

Registered Office :	Shop No. 41, Manisha Plaza, Sonapur Lane, Off LBS Marg, Kurla West, Mumbai – 400072, Maharashtra

Country :	India

Financials (as on) :	31.03.2011

Date of Incorporation :	16.01.2006

Com. Reg. No.:	11-158928

Capital Investment / Paid-up Capital :	Rs. 138.637 Millions

CIN No.: [Company Identification No.]	U52311MH2006PLC158928

TAN No.: [Tax Deduction & Collection Account No.]	MUMU04752G

PAN No.: [Permanent Account No.]	AAACU8032D

Legal Form :	A Closely Held Public Limited Liability Company

Line of Business :	Manufacturer of Pharmaceuticals.

No. of Employees :	Information declined by management

RATING & COMMENTS

MIRA’s Rating :

Ba (42)

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

Maximum Credit Limit :	USD 3330000

Status :	Satisfactory

Payment Behaviour :	Usually correct

Litigation :	Clear

Comments :	Subject is an established company having a satisfactory track record. The latest financials are not made available with the government department. As per previous year, the company performance seems to be good. Financially seems to be strong. Trade relations are reported to be fair. Business is active. Payments are reported to be usually correct and as per commitments. The company can be considered for normal business dealings at usual trade terms and conditions.

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

INDIAN ECONOMIC OVERVIEW

India is developing into an open-market economy, yet traces of its past autarkic policies remain. Economic liberalization, including industrial deregulation, privatization of state-owned enterprises, and reduced controls on foreign trade and investment, began in the early 1990s and has served to accelerate the country's growth, which has averaged more than 7% per year since 1997. India's diverse economy encompasses traditional village farming, modern agriculture, handicrafts, a wide range of modern industries, and a multitude of services. Slightly more than half of the work force is in agriculture, but services are the major source of economic growth, accounting for more than half of India's output, with only one-third of its labor force. India has capitalized on its large educated English-speaking population to become a major exporter of information technology services and software workers. In 2010, the Indian economy rebounded robustly from the global financial crisis - in large part because of strong domestic demand - and growth exceeded 8% year-on-year in real terms. However, India's economic growth in 2011 slowed because of persistently high inflation and interest rates and little progress on economic reforms. High international crude prices have exacerbated the government's fuel subsidy expenditures contributing to a higher fiscal deficit, and a worsening current account deficit. Little economic reform took place in 2011 largely due to corruption scandals that have slowed legislative work. India's medium-term growth outlook is positive due to a young population and corresponding low dependency ratio, healthy savings and investment rates, and increasing integration into the global economy. India has many long-term challenges that it has not yet fully addressed, including widespread poverty, inadequate physical and social infrastructure, limited non-agricultural employment opportunities, scarce access to quality basic and higher education, and accommodating rural-to-urban migration.

Source : CIA

EXTERNAL AGENCY RATING

Rating Agency Name	CRISIL
Rating	Long term rating : (CRISIL) BB+
Rating Explanation	Having moderate risk of default regarding timely servicing of financial obligation.
Date	March 2011

RBI DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

INFORMATION DECLINED

MANAGEMENT NON CO-OPERATIVE

LOCATIONS

Registered Office :	Shop No.41, Manisha Plaza, Sonapur Lane, Off LBS Marg, Kurla West, Mumbai – 400072, Maharashtra, India
Tel. No.:	91-22-25035173
Fax No.:	Not Available
E-Mail :	unijulesbom@yahoo.co.in info@unijules.com alihatimh@gmail.com compliance@unijules.com
Website :	http://www.unijules.com
Location :	Owned

Corporate Office/ Factory 1:	Universal Square, No. 1505/1, Shanti Nagar, Nagpur – 440001, Maharashtra, India
Tel. No.:	91-712-2768512/ 6842/ 2762589
Fax No.:	91-712-2763212/ 2589
Email :	sales@revayur.com pallavi.aloni@revayur.com
Location :	Owned

Factory 2:	B – 35, MIDC, Kalmeshwar. District, Nagpur, Maharashtra, India

Research and Development :	P - 338, Kalmeshwar MIDC, District Nagpur, Maharashtra, India

DIRECTORS

AS ON 29.09.2012

Name :	Mr. Faiz Zakir Vali
Designation :	Managing Director
Address :	Universal Pharmacy, Plot No. 545, Shantinagar, Nayapura , Nagpur - 440002 Maharashtra, India
Date of Birth/Age :	25.02.1967
Qualification :	MBA. B Pharm
Date of Appointment :	25.09.2010
PAN No.:	ABBPV9750E
DIN No.:	01809196

Name :	Mr. Dharampal Keshawdas Bellani
Designation :	Whole Time Director
Address :	Block No. 371/B, Gurunanak Nagar, Jaripatka, Nagpur - 440014, Maharashtra, India
Date of Birth/Age :	30.04.1956
Qualification :	B. Pharm
Date of Appointment :	25.09.2010
PAN No.:	ABNPB0886F
DIN No.:	01824596

Name :	Mr. Naresh Janardan Gaikwad
Designation :	Director
Address :	A2-104, Mhada Colony, Amravati Road, Nagpur – 440001, Maharashtra, India
Date of Birth/Age :	22.12.1954
Qualification :	M. Pharm, Ph. D in Medical Sciences
Date of Appointment :	30.09.2010
DIN No.:	02185462

Name :	Mr. Vaibhav Shantaram Deshpande
Designation :	Director
Address :	F. No. 2, Plot No. 224, Gulmohar Society, Nanadavan Main Road, Nagpur – 440009, Maharashtra, India
Date of Birth/Age :	17.07.1982
Qualification :	B. Com
Date of Appointment :	30.09.2010
DIN No.:	02725850

Name :	Mr. Veerendra VijayKumar Parashar
Designation :	Director
Address :	13-P, Bharat Nagar, Nagpur – 440033, Maharashtra, India
Date of Birth/Age :	04.11.1940
Qualification :	M. Pharm, Ph. D in Pharmaceutical Chemistry
Date of Appointment :	30.09.2010
DIN No.:	02456416

Name :	Mr. Amit Ashok Gupta
Designation :	Director
Address :	Budhwari Reshaoli, Nagpur – 440002, Maharashtra, India
Date of Birth/Age :	09.08.1977
Qualification :
Date of Appointment :	08.04.2012
DIN No.:	05206416

Name :	Mr. Gulam Abbas Hassonjee
Designation :	Director
Address :	202, Radhe Apartment, Mecosabagh, Clark Town, Nagpur – 440004, Maharashtra, India
Date of Birth/Age :	13.04.1941
Qualification :
Date of Appointment :	21.08.2012
DIN No.:	00162445

KEY EXECUTIVES

Name :	Ms. Shilpa Pawankar
Designation :	Company Secretary
Address :	Plot No. 12, Adarsh Wadi, Amaravati Road, Nagpur – 440023, Maharashtra, India
Date of Birth/Age :	12.06.1986
Date of Appointment :	12.01.2010
PAN No.:	BDSPP0606B

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

AS ON 29.09.2012

Names of Shareholders		No. of Shares
Faiz Zakir Vali		8313684
Nitish Shastri		2000
Esa Mohammad Vali		2000
Shehrebano Vali		2000
Rajeev Jidewar		2000
Sharmishtha U. Khobragade		2000
Astra Exim Private Limited, India		2225500
Benzo Petro International Limited, India		468750
Virtuous Capital Limited (Formally known as Finaventure Advisory Services (India) Limited), India		2781200
Pranav Financial Services Private Limited, India		64516
Total		13863650

AS ON 29.09.2012

Equity Share Breakup		Percentage of Holding
Category
Bodies corporate		39.96
Directors or relatives of directors		60.00
Other top fifty shareholders		0.04
Total		100.00

BUSINESS DETAILS

Line of Business :

Manufacturer of Pharmaceuticals.

Products :

ITC Code	Product Descriptions
300310	Pharmaceuticals

PRODUCTION STATUS (AS ON 31.03.2011)

Particulars	Unit	Actual Production
Allopathic :
Liquid (in 000)	Ltrs	3590191.70
Ointment	Kgs.	70163.72
Powder	Kgs.	8379.35
Capsulses ('000)	Nos.	10476.71
Injection :
Vials/ Ampoules	Nos	56871415.00
Herbal :
Liquid	Ltrs	437100.79
Tablets ('000)	Nos.	82037.16
Capsulses ('000)	Nos.	71590.77
Powder	Kgs.	2243211.02

GENERAL INFORMATION

No. of Employees :

Information declined by management

Bankers :

Ø Bank of Maharashtra, Mid Corporate Branch Mahabank Bhavan Sitabuldi, Nagpur - 440012, Maharashtra, India

Ø State Bank of India, Industrial Finance Branch, World Trade Centre, Cuffe Parade, Mumbai - 400005, Maharashtra, India

Ø The Shamrao Vithal Co-Operative Bank Limited, Yamuna Sadan, Saki Vihar Road, Sakinaka, Andheri (East),, Mumbai - 400072, Maharashtra, India

Ø Bank of Baroda

Ø Allahabad Bank

Facilities :

Secured Loans	31.03.2011	31.03.2010
	(Rs. In Millions)
Rupee term loans banks secured	284.315	210.190
Rupee term loans financial institutions secured	2.138	1.158
Total	286.453	211.348

Unsecured Loans	31.03.2011	31.03.2010
	(Rs. In Millions)
Other external commercial borrowings unsecured	27.946	1.040
Other debt unsecured	0.000	0.338
Total	27.946	1.378


Banking Relations :	--

Auditors :
Name :	Husain Ali Hatim Shabbir Chartered Accountants
Address :	315 B Ashirwad Complex, Ramdaspeth, Nagpur – 440012, Maharashtra, India
Tel. No.:	91-712-2420204
Fax No.:	91-712-2420204
Income-tax PAN of auditor or auditor's firm :	ABCPH6547G

Subsidiaries :	Ø Zim Laboratories Limited [CIN No.: L99999MH1984PLC032172] Ø RevAyur Beauty Care India Private Limited [CIN No.: U93090MH2009PTC196258]

Associates :	Ø Akasa Advertisement Ø Universal Medicaments Private Limited Ø Universal Pharmacy Ø Universal Ayurvaid Ø City Pharmacy Ø Saif Health Remedies Private Limited Ø Herbatone Specialities Private Limited [U24230MH1987PTC043070]

CAPITAL STRUCTURE

AS ON 31.03.2011

Authorised Capital :

No. of Shares	Type	Value	Amount

25000000	Equity Shares	Rs. 10/- each	Rs. 250.000 Millions

Issued, Subscribed & Paid-up Capital :

No. of Shares	Type	Value	Amount

13863650	Equity Shares	Rs. 10/- each	Rs. 138.637 Millions

FINANCIAL DATA

[all figures are in Rupees Millions]

ABRIDGED BALANCE SHEET

SOURCES OF FUNDS		31.03.2011	31.03.2010	31.03.2009
SHAREHOLDERS FUNDS
1] Share Capital		138.637	138.637	66.974
2] Share Application Money		0.000	0.000	4.740
3] Reserves & Surplus		693.413	481.935	354.833
4] (Accumulated Losses)		0.000	0.000	0.000
NETWORTH		832.050	620.572	426.547
LOAN FUNDS
1] Secured Loans		286.453	211.348	487.530
2] Unsecured Loans		27.946	1.378	0.338
TOTAL BORROWING		314.399	212.726	487.868
DEFERRED TAX LIABILITIES		23.383	20.303	21.934

TOTAL		1169.832	853.601	936.349

APPLICATION OF FUNDS

FIXED ASSETS [Net Block]		430.642	298.132	242.365
Capital work-in-progress		157.833	38.089	0.000

INVESTMENT		33.636	30.616	30.616
DEFERREX TAX ASSETS		0.000	0.000	0.000

CURRENT ASSETS, LOANS & ADVANCES
	Inventories	308.766	304.922	191.428
	Sundry Debtors	1071.959	694.667	524.516
	Cash & Bank Balances	103.651	16.270	12.404
	Other Current Assets	0.000	0.000	0.000
	Loans & Advances	179.212	279.545	139.216
Total Current Assets		1663.588	1295.404	867.564
Less : CURRENT LIABILITIES & PROVISIONS
	Sundry Creditors	274.564	193.828	129.919
	Other Current Liabilities	781.374	537.044	38.609
	Provisions	67.667	78.863	38.219
Total Current Liabilities		1123.605	809.735	206.747
Net Current Assets		539.983	485.669	660.817

MISCELLANEOUS EXPENSES		7.738	1.095	2.551

TOTAL		1169.832	853.601	936.349

PROFIT & LOSS ACCOUNT

	PARTICULARS		31.03.2011	31.03.2010	31.03.2009
	SALES
		Income	2685.680	1982.636	1637.905
		Other Income	3.586	1.138	9.543
		TOTAL	2689.266	1983.774	1647.448

Less	EXPENSES
		Consumption materials changes inventories	2097.600	1530.006
		Manufacturing service costs	27.978	18.715
		Employee related expenses	42.755	38.003
		Administrative selling other expenses	107.537	98.552
		Research development expenditure	4.616	3.586
		TOTAL	2280.486	1688.862	1442.971

Less	PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION		408.780	294.912	204.477

Less	FINANCIAL EXPENSES		93.489	71.424	60.133

	PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION		315.291	223.488	144.344

Less/ Add	DEPRECIATION/ AMORTISATION		14.908	11.219	9.184

	PRIOR PERIOD ITEMS BEFORE TAX		0.478	0.091	0.000

	PROFIT BEFORE TAX		299.905	212.178	135.160

Less	TAX		88.428	86.014	53.981

	PROFIT AFTER TAX		211.477	126.164	81.179

Add	PREVIOUS YEARS’ BALANCE BROUGHT FORWARD		301.472	175.308	94.129

	BALANCE CARRIED TO THE B/S		512.949	301.472	175.308

	Earnings Per Share (Rs.)		15.25	9.39	6.62

KEY RATIOS

PARTICULARS		31.03.2011	31.03.2010	31.03.2009
PAT / Total Income	(%)	7.86	6.36	4.93

Net Profit Margin (PBT/Sales)	(%)	11.17	10.70	8.25

Return on Total Assets (PBT/Total Assets}	(%)	14.32	13.31	12.18

Return on Investment (ROI) (PBT/Networth)		0.36	0.34	0.32

Debt Equity Ratio (Total Liability/Networth)		1.73	1.65	1.63

Current Ratio (Current Asset/Current Liability)		1.48	1.60	4.20

LOCAL AGENCY FURTHER INFORMATION

SUNDRY CREDITORS DETAILS:

Particulars	31.03.2011	31.03.2010	31.03.2009
	(Rs. In Millions)
Creditors due small micro enterprises	0.000	0.000	0.000
Creditors due others	274.564	193.828	129.919
Sundry creditors	274.564	193.828	129.919

Sr. No.	Check List by Info Agents	Available in Report (Yes / No)
1]	Year of Establishment	Yes
2]	Locality of the firm	Yes
3]	Constitutions of the firm	Yes
4]	Premises details	No
5]	Type of Business	Yes
6]	Line of Business	Yes
7]	Promoter's background	Yes
8]	No. of employees	No
9]	Name of person contacted	No
10]	Designation of contact person	No
11]	Turnover of firm for last three years	Yes
12]	Profitability for last three years	Yes
13]	Reasons for variation <> 20%	--
14]	Estimation for coming financial year	No
15]	Capital in the business	Yes
16]	Details of sister concerns	Yes
17]	Major suppliers	No
18]	Major customers	No
19]	Payments terms	No
20]	Export / Import details (if applicable)	No
21]	Market information	--
22]	Litigations that the firm / promoter involved in	--
23]	Banking Details	Yes
24]	Banking facility details	Yes
25]	Conduct of the banking account	--
26]	Buyer visit details	--
27]	Financials, if provided	Yes
28]	Incorporation details, if applicable	Yes
29]	Last accounts filed at ROC	No
30]	Major Shareholders, if available	Yes
31]	Date of Birth of Proprietor/Partner/Director, if available	Yes
32]	PAN of Proprietor/Partner/Director, if available	Yes
33]	Voter ID No of Proprietor/Partner/Director, if available	No
34]	External Agency Rating, if available	Yes

BUSINESS OUTLOOK:

Some of the major milestones crossed during the year were,

Attained AYUSH certification from the Department of AYUSH, Government of India. They are the 1st company to get this mark in India and also the 1st to get it renewed. Attained DSIR recognition for their R and D infrastructure thus becoming a certified R and D house as well as being eligible for various incentives. Total Number of dossiers filed for registrations in different countries across the world has grown 3 times thus ensuring sufficient business in the future. Once again, ethical division has shown double digit growth and also expanded to markets of Orissa and M.P. and increased presence in Maharashtra and Chattisgarh which has resulted in improved YPM profile. Overall REVAYUR branding continues to expand with major markets of the South like Kerala and Tamil Nadu providing tremendous response. Market coverage other than Big Bazaars also increased drastically with product availability at new beauty stores all across the central and south of India. On the international front, major inroads were made by registrations of 10 products in 19 countries of the franco African belt, launch of Semi Solids range in the ethical market of Sri Lanka and African countries. On the injectable front, business from major institutions was obtained for the contrast media range by active participation in tenders and activation of a team of promoters. Further, other than contrast business has also stabilized thus reducing the dependency on contrast. Product development in the critical care segment has also progressed satisfactorily. After WHO certification of the injectable units, major inroads have been made into the registration of the contrast media product in semi regulated markets and business increase in this segment is expected to be a major windfall for the company.

On the management and infrastructure front,

Integrated common ERP platform has been successfully implemented on line across all locations resulting in improved reporting and efficiency in operations. Combined H.R department established for uniform implementation of policies across the group. Work on the new integrated herbal manufacturing facility was started with the capacities scheduled to come on line by March 2012. Efficiency audits conducted at the injectable plant thus improving productivity by 23 % without any capital expenses.

CONTINGENT LIABILITIES

(Rs. In Millions)

Particular	31.03.2011
Estimated amount of Unexecuted Capital contracts (Net of advance and deposits)	-
Outstanding Guarantee and Counter guarantees to various banks, in respect of the guarantees given by those banks in favor of various government authorities and others	39.419
Claims against the company, not acknowledged as debts	-

FIXED ASSETS:

Ø Land

Ø Factory Building

Ø Plant and Machinery

Ø AHU

Ø Electric Installation

Ø Laboratory Equipments

Ø Office Equipments

Ø Computer Accessories

Ø E.P.A.B.X.

Ø Vehicles

Ø Furniture and Fixture

Ø Borwell

Ø Canteen Utensils

Ø Trade Mark

CMT REPORT (Corruption, Money Laundering & Terrorism]

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

1] INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

2] Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

3] Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

4] Record on Financial Crime :

Charges or conviction registered against subject: None

5] Records on Violation of Anti-Corruption Laws :

Charges or investigation registered against subject: None

6] Records on Int’l Anti-Money Laundering Laws/Standards :

Charges or investigation registered against subject: None

7] Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

8] Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

9] Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

10] Press Report :

No press reports / filings exists on the subject.

CORPORATE GOVERNANCE

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

CONTRAVENTION

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs. 55.33
UK Pound	1	Rs. 89.05
Euro	1	Rs. 72.57

INFORMATION DETAILS

Information Gathered by :	PJA

Report Prepared by :	BVA

SCORE & RATING EXPLANATIONS

SCORE FACTORS	RANGE	POINTS
HISTORY	1~10	4
PAID-UP CAPITAL	1~10	4
OPERATING SCALE	1~10	5
FINANCIAL CONDITION
--BUSINESS SCALE	1~10	5
--PROFITABILIRY	1~10	5
--LIQUIDITY	1~10	5
--LEVERAGE	1~10	5
--RESERVES	1~10	4
--CREDIT LINES	1~10	5
--MARGINS	-5~5	-
DEMERIT POINTS
--BANK CHARGES	YES/NO	YES
--LITIGATION	YES/NO	NO
--OTHER ADVERSE INFORMATION	YES/NO	NO
MERIT POINTS
--SOLE DISTRIBUTORSHIP	YES/NO	NO
--EXPORT ACTIVITIES	YES/NO	NO
--AFFILIATION	YES/NO	YES
--LISTED	YES/NO	NO
--OTHER MERIT FACTORS	YES/NO	YES
TOTAL		42

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
-	NB	New Business	-

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.

MIRA INFORM REPORT

308.766

191.428

1071.959

524.516

103.651

12.404

0.000

0.000

179.212

139.216

1663.588

274.564

781.374

67.667

1123.605

539.983

4.93

8.25

12.18

0.32

1.63

4.20

274.564

Unit